

# David N Church

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4606415/publications.pdf>

Version: 2024-02-01

55  
papers

4,673  
citations

147801

31  
h-index

182427

51  
g-index

58  
all docs

58  
docs citations

58  
times ranked

6739  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. <i>Nature Communications</i> , 2022, 13, 1373.	12.8	47
2	Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. <i>Journal of Pathology</i> , 2022, 257, 340-351.	4.5	11
3	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. <i>American Journal of Human Genetics</i> , 2022, 109, 953-960.	6.2	23
4	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. <i>British Journal of Cancer</i> , 2021, 124, 786-796.	6.4	11
5	Abstract IA015: Molecular stratification: Beyond TCGA. , 2021, , .		0
6	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	6.4	113
7	Evaluation of treatment effects in patients with endometrial cancer and <i>POLE</i> mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021, 127, 2409-2422.	4.1	62
8	Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. <i>Cancers</i> , 2021, 13, 4538.	3.7	8
9	Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer. <i>EBioMedicine</i> , 2021, 71, 103547.	6.1	4
10	Interpretation of somatic <i>POLE</i> mutations in endometrial carcinoma. <i>Journal of Pathology</i> , 2020, 250, 323-335.	4.5	203
11	Clinicopathological and molecular characterisation of a "multiple-classifier"™ endometrial carcinomas. <i>Journal of Pathology</i> , 2020, 250, 312-322.	4.5	205
12	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. <i>ESMO Open</i> , 2020, 5, e001040.	4.5	6
13	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 283-296.	3.0	17
14	The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability. <i>Clinical Epigenetics</i> , 2020, 12, 102.	4.1	8
15	Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. <i>Lancet</i> , 2020, 395, 350-360.	13.7	364
16	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or <i>POLE</i> exonuclease domain mutant colon cancer: a phase III randomised study. <i>ESMO Open</i> , 2020, 5, e000638.	4.5	47
17	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1508-1519.	3.4	45
18	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. <i>British Journal of Cancer</i> , 2019, 121, 474-482.	6.4	41

#	ARTICLE	IF	CITATIONS
19	ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility studyâ€”PRECISE study. <i>Cancer Medicine</i> , 2019, 8, 6305-6314.	2.8	6
20	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 784-796.	3.4	141
21	Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 1087-1097.	7.0	113
22	Somatic <i>POLE</i> exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. <i>Journal of Pathology</i> , 2018, 245, 283-296.	4.5	71
23	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002279.	1.2	21
24	Adjuvant Treatment for <i>POLE</i> Proofreading Domainâ€”Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. <i>Clinical Cancer Research</i> , 2018, 24, 3197-3203.	7.0	50
25	Changing Practice Evaluationâ€”Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocolsâ€”Experience From a Supraregional Center. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 240-244.	1.9	8
26	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 635-643.	8.1	60
27	Tumour-infiltrating CD8+ lymphocytes as a prognostic marker in colorectal cancer: A retrospective, pooled analysis of the QUASAR2 and VICTOR trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3515-3515.	1.6	4
28	Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 152-156.	1.9	25
29	Hypermutated Colorectal Cancer and Neoantigen Load. , 2017, , 187-215.		3
30	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i> -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>Oncolmmunology</i> , 2017, 6, e1264565.	4.6	102
31	CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. <i>Oncolmmunology</i> , 2017, 6, e1338230.	4.6	116
32	Cancer predisposition syndromes: lessons for truly precision medicine. <i>Journal of Pathology</i> , 2017, 241, 226-235.	4.5	13
33	Neopeptides and CD3-Positive and CD8-Positive Cells in Polymerase $\epsilon$ -Mutated and Microsatellite-Instable Endometrial Cancers. <i>JAMA Oncology</i> , 2016, 2, 141.	7.1	2
34	Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016, 48, 667-674.	21.4	77
35	Somatic <i>POLE</i> proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216.	8.1	227
36	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1543-1557.	10.7	129

#	ARTICLE	IF	CITATIONS
37	Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. <i>Nature Communications</i> , 2016, 7, 11111.	12.8	83
38	A panoply of errors: polymerase proofreading domain mutations in cancer. <i>Nature Reviews Cancer</i> , 2016, 16, 71-81.	28.4	292
39	Vaccination of chemotherapy patients—effect of guideline implementation. <i>Supportive Care in Cancer</i> , 2016, 24, 2317-2321.	2.2	17
40	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. <i>Modern Pathology</i> , 2016, 29, 174-181.	5.5	68
41	<i>POLE</i> proofreading mutation, immune response and prognosis in endometrial cancer. <i>OncImmunology</i> , 2016, 5, e1072675.	4.6	34
42	<i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3347-3355.	7.0	249
43	Prognostic Significance of <i>POLE</i> Proofreading Mutations in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 402.	6.3	229
44	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015, 28, 836-844.	5.5	343
45	Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 363-371.	0.5	4
46	What is the extent of the advantage of video-assisted thoracoscopic surgical resection over thoracotomy in terms of delivery of adjuvant chemotherapy following non-small-cell lung cancer resection?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2014, 19, 656-660.	1.1	20
47	'Toxgnostics': an unmet need in cancer medicine. <i>Nature Reviews Cancer</i> , 2014, 14, 440-445.	28.4	29
48	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1031-1039.	1.6	216
49	Evaluation of <i>PIK3CA</i> Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4297-4305.	1.6	181
50	In Reply: Response to Marioni. <i>Current Oncology Reports</i> , 2013, 15, 3-3.	4.0	0
51	DNA polymerase $\epsilon$ and $\delta$ exonuclease domain mutations in endometrial cancer. <i>Human Molecular Genetics</i> , 2013, 22, 2820-2828.	2.9	319
52	Survivin in Solid Tumors: Rationale for Development of Inhibitors. <i>Current Oncology Reports</i> , 2012, 14, 120-128.	4.0	98
53	A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S35.	0.1	0
54	Extended Survival in Women With Brain Metastases From HER2 Overexpressing Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 250-254.	1.3	66

#	ARTICLE	IF	CITATIONS
55	Clinical review “ Small cell carcinoma of the bladder. Cancer Treatment Reviews, 2006, 32, 588-593.	7.7	39